343 related articles for article (PubMed ID: 18362173)
1. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.
Flex E; Petrangeli V; Stella L; Chiaretti S; Hornakova T; Knoops L; Ariola C; Fodale V; Clappier E; Paoloni F; Martinelli S; Fragale A; Sanchez M; Tavolaro S; Messina M; Cazzaniga G; Camera A; Pizzolo G; Tornesello A; Vignetti M; Battistini A; Cavé H; Gelb BD; Renauld JC; Biondi A; Constantinescu SN; Foà R; Tartaglia M
J Exp Med; 2008 Apr; 205(4):751-8. PubMed ID: 18362173
[TBL] [Abstract][Full Text] [Related]
2. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
3. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.
Li Q; Li B; Hu L; Ning H; Jiang M; Wang D; Liu T; Zhang B; Chen H
Oncotarget; 2017 May; 8(21):34687-34697. PubMed ID: 28410228
[TBL] [Abstract][Full Text] [Related]
5. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
[TBL] [Abstract][Full Text] [Related]
7. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
[TBL] [Abstract][Full Text] [Related]
8. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.
Hornakova T; Chiaretti S; Lemaire MM; Foà R; Ben Abdelali R; Asnafi V; Tartaglia M; Renauld JC; Knoops L
Blood; 2010 Apr; 115(16):3287-95. PubMed ID: 20167706
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
[TBL] [Abstract][Full Text] [Related]
10. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Kleppe M; Soulier J; Asnafi V; Mentens N; Hornakova T; Knoops L; Constantinescu S; Sigaux F; Meijerink JP; Vandenberghe P; Tartaglia M; Foa R; Macintyre E; Haferlach T; Cools J
Blood; 2011 Jun; 117(26):7090-8. PubMed ID: 21551237
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
Loh ML; Zhang J; Harvey RC; Roberts K; Payne-Turner D; Kang H; Wu G; Chen X; Becksfort J; Edmonson M; Buetow KH; Carroll WL; Chen IM; Wood B; Borowitz MJ; Devidas M; Gerhard DS; Bowman P; Larsen E; Winick N; Raetz E; Smith M; Downing JR; Willman CL; Mullighan CG; Hunger SP
Blood; 2013 Jan; 121(3):485-8. PubMed ID: 23212523
[TBL] [Abstract][Full Text] [Related]
12. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.
Xiang Z; Zhao Y; Mitaksov V; Fremont DH; Kasai Y; Molitoris A; Ries RE; Miner TL; McLellan MD; DiPersio JF; Link DC; Payton JE; Graubert TA; Watson M; Shannon W; Heath SE; Nagarajan R; Mardis ER; Wilson RK; Ley TJ; Tomasson MH
Blood; 2008 May; 111(9):4809-12. PubMed ID: 18160671
[TBL] [Abstract][Full Text] [Related]
13. Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Lim M; Batista CR; de Oliveira BR; Creighton R; Ferguson J; Clemmer K; Knight D; Iansavitchous J; Mahmood D; Avino M; DeKoter RP
Mol Cell Biol; 2020 Aug; 40(18):. PubMed ID: 32631903
[TBL] [Abstract][Full Text] [Related]
14. Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia.
Guo X; Zhang R; Liu J; Li M; Song C; Dovat S; Li J; Ge Z
PLoS One; 2015; 10(5):e0125429. PubMed ID: 25942645
[TBL] [Abstract][Full Text] [Related]
15. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of JAK1 gene in human hepatocellular carcinoma.
Xie HJ; Bae HJ; Noh JH; Eun JW; Kim JK; Jung KH; Ryu JC; Ahn YM; Kim SY; Lee SH; Yoo NJ; Lee JY; Park WS; Nam SW
Neoplasma; 2009; 56(2):136-40. PubMed ID: 19239328
[TBL] [Abstract][Full Text] [Related]
17. Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.
Gordon GM; Lambert QT; Daniel KG; Reuther GW
Biochem J; 2010 Dec; 432(2):255-65. PubMed ID: 20868368
[TBL] [Abstract][Full Text] [Related]
18. The molecular genetic makeup of acute lymphoblastic leukemia.
Mullighan CG
Hematology Am Soc Hematol Educ Program; 2012; 2012():389-96. PubMed ID: 23233609
[TBL] [Abstract][Full Text] [Related]
19. Lymphoid malignancies: Another face to the Janus kinases.
Scott LM
Blood Rev; 2013 Mar; 27(2):63-70. PubMed ID: 23340138
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
